Growth hormone peptides in Cayman: not controlled, still regulated

Growth hormone secretagogues are among the peptides physicians are asked about most: tesamorelin, a growth hormone-releasing factor analogue tested in randomized trials, and unapproved molecules such as ipamorelin, CJC-1295 and GHRP-6, often marketed together as "stacks" such as Tesamorelin + Ipamorelin. In the Cayman Islands, the law treats these products very differently from the way the United Kingdom or the United States treats growth hormone itself. The Misuse of Drugs Act (2026 Revision) does not list them, and it does not list growth hormone or anabolic steroids either¹. Their legal home is the Pharmacy Law, 1979².

What the Misuse of Drugs Act (2026 Revision) lists, and what it leaves out

Schedule 1 of the Act, as consolidated on 31 December 2025, sets out three parts of controlled drugs¹. Part 1 holds the opioids, cocaine, fentanyl analogues, hallucinogens and synthetic opioids such as the nitazenes; Part 2 holds codeine-type drugs, cannabis and barbiturates; Part 3 holds the benzodiazepines, buprenorphine and stimulant appetite suppressants such as phentermine¹. No growth hormone, no growth hormone-releasing peptide and no anabolic-androgenic steroid appears in any of the three parts¹. The offences in section 3 of the Act (importing, supplying, dispensing, prescribing or possessing a controlled drug without authority) therefore do not reach these products¹.

How the UK and the US compare

In the UK, Part III of Schedule 2 of the Misuse of Drugs Act 1971 (Class C) lists "Somatotropin", "Somatrem" and "Somatropin", "Chorionic Gonadotrophin (HCG)", and anabolic steroids including "Testosterone" and "Nandrolone"⁶. In the United States, 21 U.S.C. 333(e) makes it an offence to knowingly distribute, or possess with intent to distribute, "human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition", punishable by "not more than 5 years in prison"; the statute defines human growth hormone as "somatrem, somatropin, or an analogue of either of them"⁷. Neither list names the secretagogue peptides themselves; in both countries those are handled as medicines, not as controlled drugs⁶⁷.

Where the Pharmacy Law, 1979 comes in

In the Cayman Islands, prescription medicines fall under the Pharmacy Law, 1979, which controls "pharmaceutical products having potential danger to health if misapplied"². A restricted pharmaceutical is one prescribed as such by regulation "which may not be dispensed or administered except under prescription"². Section 11 makes it an offence for anyone other than the Chief Medical Officer, a medical practitioner, the Chief Agricultural Officer or a pharmacist to import, dispense or otherwise deal in restricted pharmaceuticals; section 12 bars a pharmacist from dispensing one without a prescription; section 18 requires restricted pharmaceuticals to be labeled with their contents and intended use². The penalty in section 20 is a fine not exceeding $1,000 or imprisonment for up to six months, or both².

Facilities matter too. Under the Health Practice Act (2026 Revision), operating a health care facility without a certificate from the Health Practice Commission is an offence punishable by a fine of fifty thousand dollars plus ten thousand dollars for every day the offence continues¹⁰. The Pharmacy Bill, 2024, passed but listed as not in force, would add an offence of importing, prescribing or administering a non-approved medicine, punishable by twenty thousand dollars, five years in prison, or both¹¹¹². Under the Bill's definitions, an approved medicine is one approved in a country prescribed by regulations, approved by the Pharmacy Council, or covered by an exceptional or emergency use authorization¹¹.

What the evidence on growth hormone peptides shows

The evidence is uneven. Tesamorelin is the best-studied: in a randomized trial of 412 adults with HIV and abdominal fat accumulation, 26 weeks of the growth hormone-releasing factor analogue reduced visceral adipose tissue by 15.2%, against a 5.0% rise with placebo, and raised IGF-I by 81.0%³. Ipamorelin was described in 1998, in rat and swine studies, as "the first selective growth hormone secretagogue": unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol even at doses more than 200-fold above its effective dose⁴. CJC-1295, a long-acting GHRH analogue, raised growth hormone 2- to 10-fold for 6 or more days and IGF-I 1.5- to 3-fold for 9 to 11 days after a single dose in healthy adults, with an estimated half-life of 5.8 to 8.1 days⁵. None of these studies tested anti-aging claims in healthy people.

Growth hormone itself was tested in healthy older adults. A systematic review of randomized trials (31 articles, 18 study populations) found "small changes in body composition and increased rates of adverse events", with significantly more soft tissue edema, arthralgias, carpal tunnel syndrome and gynecomastia, and concluded that growth hormone "cannot be recommended as an antiaging therapy"⁹.

Regulators have flagged the secretagogues for safety. The US FDA's list of bulk drug substances that may present significant safety risks in compounding includes ipamorelin acetate, noting that "A study published in literature identified serious adverse events including death" with intravenous use, and GHRP-6, citing immunogenicity, possible effects on cortisol and increased blood glucose⁸. For CJC-1295, the FDA states that it "has identified serious adverse events associated with CJC-1295 including increased heart rate"⁸.